In an open-label phase II trial , patients with advanced NSCLC , EGFR wild-type or unknown , PS 0-2 , in whom initial cisplatin-based chemotherapy had failed were randomized to sequential erlotinib 150 mg/d ( day 2-16 ) + docetaxel ( 75 mg/m ( 2 ) d1 ) ( arm ED ) or docetaxel ( 75 mg/m ( 2 ) d1 ) alone ( arm D ) ( 21-day cycle ) .